Monitoring of the heparinization in the rabbit animal model during endovascular interventions
- PMID: 23619701
- DOI: 10.1007/s00234-013-1189-y
Monitoring of the heparinization in the rabbit animal model during endovascular interventions
Abstract
Introduction: The purpose of this study was to monitor and to optimize heparinization during endovascular procedures in the New Zealand White Rabbit (NZWR) model.
Methods: Right common carotid artery aneurysms were surgically created in 43 NZWR, with an average weight of 4,330 g (range 3,500-5,430 g). The activated partial thromboplastin time (aPTT) was measured during different stages of the interventional procedures. Blood samples were taken before and 10 min after administration of heparin and at the end of each endovascular procedure. We compared three different experimental groups: 100 U heparin, 500 U heparin and 100 U heparin plus pretreatment with aspirin and clopidogrel. The individual aPTT values were measured using a ball coagulometer.
Results: The average baseline aPTT in the rabbit is 75.2 ± 18.9 s compared to a mean of 33 s (range 26-40 s) in humans. The dosages of heparin used achieved anticoagulation in all cases. Five hundred units of heparin increased the aPTT significantly more than 100 U. No difference was found between the aPTT obtained from the 100 U and the 100 U plus pretreatment group, as aspirin and clopidogrel do not affect the coagulation cascade.
Conclusion: One hundred units of heparin can achieve anticoagulation in a similar magnitude as needed in interventional procedures in humans. This fact enhances suitability of the rabbit animal model for the testing of intravascular devices.
Similar articles
-
Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention.Ann Vasc Surg. 2019 Oct;60:286-292. doi: 10.1016/j.avsg.2019.02.033. Epub 2019 May 7. Ann Vasc Surg. 2019. PMID: 31075466
-
Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.Ann Pharmacother. 2011 Jul;45(7-8):861-8. doi: 10.1345/aph.1Q161. Epub 2011 Jun 28. Ann Pharmacother. 2011. PMID: 21712506
-
Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.J Vasc Surg. 2018 Aug;68(2):400-407. doi: 10.1016/j.jvs.2017.11.079. Epub 2018 Mar 20. J Vasc Surg. 2018. PMID: 29571622
-
Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.Tex Heart Inst J. 1993;20(4):258-63. Tex Heart Inst J. 1993. PMID: 8298321 Free PMC article. Review.
-
No Concluding Evidence on Optimal Activated Clotting Time for Non-cardiac Arterial Procedures.Eur J Vasc Endovasc Surg. 2020 Jan;59(1):137-147. doi: 10.1016/j.ejvs.2019.08.007. Epub 2019 Nov 4. Eur J Vasc Endovasc Surg. 2020. PMID: 31699657
Cited by
-
Targeting myeloperoxidase to stabilize unruptured aneurysm: an imaging-guided approach.BMC Cardiovasc Disord. 2024 Mar 20;24(1):169. doi: 10.1186/s12872-024-03822-1. BMC Cardiovasc Disord. 2024. PMID: 38509468 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical